On 14 November 2022, the FDA granted accelerated approval to Mirvetuximab soravtansine (MIRV) for the treatment of patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian-tube, or primary peritoneal cancer who had already received one to three systemic treatment regimens. This evidence concerns the gene FOLR1 and peritoneum cancer.